ArticleFrontiers in endocrinology2025
The role of bile acid metabolism-related genes in prognosis assessment of hepatocellular carcinoma and identification of NPC1 as a biomarker.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Review
- Integrative multi-omics analysis reveals a gut-liver axis signature of metabolic reprogramming associated with response to transarterial chemoembolization in hepatocellular carcinoma.BMC gastroenterology · 2026Article
- Functional Role of COP1 Gene in Hepatocellular Carcinoma Lipid Metabolism and Stemness.Genes to cells : devoted to molecular & cellular mechanisms · 2026Article
- Comprehensive Multi-Omics Characterization of CYP2R1 as a Diagnostic and Functional Biomarker in Hepatocellular Carcinoma.Medical sciences (Basel, Switzerland) · 2026Article
- Gut microbiota-derived metabolites in immunomodulation and gastrointestinal cancer immunotherapy.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is one of the most prevalent and deadly cancers worldwide, with a high recurrence rate and poor prognosis. Understanding the molecular mechanisms driving HCC progression is crucial for improving prognostic accuracy and developing targeted therapies. Bile acids (BAs), as critical regulators of liver metabolism and inflammation, have recently been implicated in tumorigenesis and cancer progression. In particular, bile acids metabolism (BAM)-related genes play a pivotal role in the regulation of cellular proliferation, apoptosis, and immune responses in HCC. In this study, we explored the prognostic significance of BAM-related genes in HCC. Using a comprehensive bioinformatics approach, we analyzed transcriptomic data from public databases, identifying 111 differentially expressed BAM-related genes associated with patient survival. We then constructed a prognostic model based on these key genes, utilizing multivariate Cox regression analysis to determine their independent predictive value for overall survival in HCC patients. We identified four key BAM-related genes including AKR1D1, CYP7A1, FABP6, and NPC1 as significant prognostic markers. Among these genes, only NPC1 was the highly expressed gene and demonstrated statistically difference between HCC and normal liver tissues. The downregulation of NPC1 inhibited HepG2 cell proliferation, migration, and invasion. In conclusion, BAM-related genes offer a promising avenue for improving prognosis assessment in HCC patients. Our findings highlight the potential of NPC1 as a valuable tool for risk stratification and personalized treatment strategies in HCC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.